Welcome to our dedicated page for Hemogenyx Pharma news (Ticker: HOPHF), a resource for investors and traders seeking the latest updates and insights on Hemogenyx Pharma stock.
Hemogenyx Pharmaceuticals plc develops clinical-stage biopharmaceutical therapies for blood and autoimmune diseases. Company news centers on HG-CT-1, its CAR-T cell therapy program for relapsed or refractory acute myeloid leukemia, including FDA IND reporting, clinical development updates, product stability work and lentiviral-vector manufacturing processes.
Recurring announcements also cover the company's CDX and CBR product candidates, platform technologies used for novel product development, and capital-market actions such as equity issuance, warrant exercises, prospectus publication, total voting rights and admissions of ordinary shares to trading on the London Stock Exchange.
Hemogenyx Pharmaceuticals (OTC:HOPHF, LSE:HEMO) granted new share options and extended an investor warrant term.
The Board granted 1,200,000 options to directors and the medical director and 60,000 to employees, all at an 8p exercise price, expiring 29 May 2031, vesting immediately. Total options now cover 1,410,479 shares, 20.7% of issued capital. The term of 69,048 investor warrants was extended to 7 September 2026, with all other terms unchanged.
Hemogenyx Pharmaceuticals (HOPHF) published final audited results for year ended 31 December 2025 and posted the Annual Report online. Key developments: commencement of the Phase 1 trial of HG-CT-1, DSMB clearance to enter dose-expansion, opening of a paediatric arm, and equity raises of £2.7m (2025) and £5.5m (early 2026).
The company signposted the full final results and related documents are available on its website and via the regulatory PDF link.
Hemogenyx Pharmaceuticals (OTC: HOPHF) raised £3,000,000 via direct subscription of 374,532 new ordinary shares at £8.01 per share to accelerate Phase I trials of its CAR-T therapy HG-CT-1 and begin early commercialisation under Estonia's hospital exemption pathway. Manufacturing hardware is established in Estonia and technology transfer with Cellin Technologies OÜ will commence imminently. Admission of the placing shares to the Main Market of the London Stock Exchange is expected on or around 6 May 2026, bringing the enlarged issued share capital to 6,799,961 ordinary shares.
Hemogenyx Pharmaceuticals (OTC:HOPHF) filed its second annual IND report with the FDA for HG-CT-1, a CAR-T therapy for relapsed or refractory acute myeloid leukemia, on April 14, 2026. The filing summarizes Year 2 clinical activity, manufacturing stability work, and planned dose escalation.
Key clinical details: a Phase 1 study enrolling up to 36 subjects (18 adults, 18 pediatric); three adult patients treated at the initial dose (7 × 10⁷ CAR+ cells); observed CAR-T expansion, reduced blast burden, no ICANS or dose-limiting toxicities, and mainly low-grade adverse events. Company plans further enrollment and dose escalation.
Hemogenyx Pharmaceuticals (OTC:HOPHF) announced on March 31, 2026 completion of the manufacturing tech transfer for HG-CT-1 to Made Scientific and submission of a comparability data package to the FDA. The company is ready to recruit adults at the second, increased dose and begin pediatric recruitment at the lowest dose level.
This expands the Phase 1 R/R AML program and confirms cross-site manufacturing reproducibility.
Hemogenyx Pharmaceuticals (LSE:HEMO / OTC:HOPHF) announced its total issued share capital and voting rights as of 27 February 2026. The Company reported 6,425,429 ordinary shares, none held in treasury, so the total voting rights equal 6,425,429.
Shareholders may use this figure as the denominator to assess FCA Disclosure Guidance and Transparency Rules notification obligations.
Hemogenyx Pharmaceuticals (HOPHF) received notices to exercise warrants over 50,841 new ordinary shares at exercise prices between 180p and 350p, raising £118,632.
Application will be made for the Warrant Shares to be admitted to trading, expected at 8:00 a.m. on 27 February 2026. Upon Admission the total issued shares and voting rights will be 6,425,429.
Hemogenyx Pharmaceuticals (OTC:HOPHF) announced a corrected equity issue: a direct subscription of 333,333 new ordinary shares at £7.50 each, raising £2,500,000, with three‑year one‑for‑one warrants at £9.00. Enlarged share capital will be 6,374,588 ordinary shares after Admission.
Net proceeds will primarily fund continuation and dose escalation of the Phase I HG‑CT‑1 trials in adults and initiation in pediatric patients, following a DSMB positive recommendation and FDA pediatric clearance; manufacturing has been outsourced to MADE.
Hemogenyx Pharmaceuticals (HOPHF) raised £2,500,000 via a direct subscription of 313,333 ordinary shares at £7.50 each, with three‑year one‑for‑one warrants at £9. Proceeds will primarily fund continuation of the Phase I HG‑CT‑1 trials in adult and paediatric R/R AML.
The DSMB gave a positive recommendation in October 2025 to escalate the adult dose, and the FDA cleared a Phase I paediatric study for ages 12–18. Admission of the placing shares is expected on or around 13 February 2026, bringing the enlarged share capital to 6,354,588 ordinary shares.
Hemogenyx Pharmaceuticals (OTC: HOPHF) announced an update on the admission of new ordinary shares. The FCA has scheduled the admission hearing for 5 January 2026, with admission expected on or around 6 January 2026 at 08:00.
All other details from the company’s 18 December 2025 announcement remain unchanged.